EUSA Pharma

EUSA Pharma is a specialty pharmaceutical company founded in March 2015, headquartered in the UK, with commercial operations in Europe and the USA. It focuses on oncology and other critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. The company aims to address rare diseases and offers treatments for conditions such as oral mucositis, a debilitating side effect of radiotherapy and high-dose chemotherapy. EUSA Pharma submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. With plans for further portfolio expansion through acquisitions and in-licensing, EUSA Pharma is supported by significant funding from leading life science investors. The company operates a wide distribution network, making its products available in approximately 40 countries across Europe, the Middle East, Asia, and Latin America.